Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies

M. Bobrowicz, A. Kusowska, M. Krawczyk, A. Zhylko, C. Forcados, A. Slusarczyk, J. Barankiewicz, J. Domagala, M. Kubacz, M. Šmída, L. Dostalova, K. Marhelava, K. Fidyt, M. Pepek, I. Baranowska, A. Szumera-Cieckiewicz, EM. Inderberg, S. Wälchli, M....

. 2024 ; 13 (1) : 2362454. [pub] 20240604

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24013570

Rituximab (RTX) plus chemotherapy (R-CHOP) applied as a first-line therapy for lymphoma leads to a relapse in approximately 40% of the patients. Therefore, novel approaches to treat aggressive lymphomas are being intensively investigated. Several RTX-resistant (RR) cell lines have been established as surrogate models to study resistance to R-CHOP. Our study reveals that RR cells are characterized by a major downregulation of CD37, a molecule currently explored as a target for immunotherapy. Using CD20 knockout (KO) cell lines, we demonstrate that CD20 and CD37 form a complex, and hypothesize that the presence of CD20 stabilizes CD37 in the cell membrane. Consequently, we observe a diminished cytotoxicity of anti-CD37 monoclonal antibody (mAb) in complement-dependent cytotoxicity in both RR and CD20 KO cells that can be partially restored upon lysosome inhibition. On the other hand, the internalization rate of anti-CD37 mAb in CD20 KO cells is increased when compared to controls, suggesting unhampered efficacy of antibody drug conjugates (ADCs). Importantly, even a major downregulation in CD37 levels does not hamper the efficacy of CD37-directed chimeric antigen receptor (CAR) T cells. In summary, we present here a novel mechanism of CD37 regulation with further implications for the use of anti-CD37 immunotherapies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013570
003      
CZ-PrNML
005      
20240905134310.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/2162402X.2024.2362454 $2 doi
035    __
$a (PubMed)38846084
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bobrowicz, Malgorzata $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000290785168
245    10
$a CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies / $c M. Bobrowicz, A. Kusowska, M. Krawczyk, A. Zhylko, C. Forcados, A. Slusarczyk, J. Barankiewicz, J. Domagala, M. Kubacz, M. Šmída, L. Dostalova, K. Marhelava, K. Fidyt, M. Pepek, I. Baranowska, A. Szumera-Cieckiewicz, EM. Inderberg, S. Wälchli, M. Granica, A. Graczyk-Jarzynka, M. Majchrzak, M. Poreba, CL. Gehlert, M. Peipp, M. Firczuk, M. Prochorec-Sobieszek, M. Winiarska
520    9_
$a Rituximab (RTX) plus chemotherapy (R-CHOP) applied as a first-line therapy for lymphoma leads to a relapse in approximately 40% of the patients. Therefore, novel approaches to treat aggressive lymphomas are being intensively investigated. Several RTX-resistant (RR) cell lines have been established as surrogate models to study resistance to R-CHOP. Our study reveals that RR cells are characterized by a major downregulation of CD37, a molecule currently explored as a target for immunotherapy. Using CD20 knockout (KO) cell lines, we demonstrate that CD20 and CD37 form a complex, and hypothesize that the presence of CD20 stabilizes CD37 in the cell membrane. Consequently, we observe a diminished cytotoxicity of anti-CD37 monoclonal antibody (mAb) in complement-dependent cytotoxicity in both RR and CD20 KO cells that can be partially restored upon lysosome inhibition. On the other hand, the internalization rate of anti-CD37 mAb in CD20 KO cells is increased when compared to controls, suggesting unhampered efficacy of antibody drug conjugates (ADCs). Importantly, even a major downregulation in CD37 levels does not hamper the efficacy of CD37-directed chimeric antigen receptor (CAR) T cells. In summary, we present here a novel mechanism of CD37 regulation with further implications for the use of anti-CD37 immunotherapies.
650    _2
$a lidé $7 D006801
650    12
$a antigeny CD20 $x imunologie $x metabolismus $x genetika $7 D018951
650    12
$a rituximab $x farmakologie $x terapeutické užití $7 D000069283
650    12
$a tetraspaniny $x genetika $x metabolismus $7 D059470
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a B-buněčný lymfom $x imunologie $x terapie $x genetika $x farmakoterapie $7 D016393
650    12
$a imunoterapie $x metody $7 D007167
650    _2
$a antigeny nádorové $x imunologie $x genetika $7 D000951
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a doxorubicin $x farmakologie $x aplikace a dávkování $7 D004317
650    _2
$a cyklofosfamid $x farmakologie $x terapeutické užití $7 D003520
650    _2
$a vinkristin $x farmakologie $x terapeutické užití $7 D014750
650    _2
$a monoklonální protilátky $x farmakologie $x terapeutické užití $7 D000911
650    _2
$a chimerické antigenní receptory $x imunologie $x genetika $x metabolismus $7 D000076962
650    _2
$a regulace genové exprese u nádorů $7 D015972
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kusowska, Aleksandra $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland $u Doctoral School, Medical University of Warsaw, Warsaw, Poland $u Laboratory of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
700    1_
$a Krawczyk, Marta $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland $u Laboratory of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland $u Doctoral School of Translational Medicine, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
700    1_
$a Zhylko, Andriy $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland $u Doctoral School, Medical University of Warsaw, Warsaw, Poland $u Laboratory of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
700    1_
$a Forcados, Christopher $u Translational Research Unit, Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway $1 https://orcid.org/0009000350731522
700    1_
$a Slusarczyk, Aleksander $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland $u Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Barankiewicz, Joanna $u Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland $u Faculty of Medicine, Lazarski University, Warsaw, Poland
700    1_
$a Domagala, Joanna $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Kubacz, Matylda $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Šmída, Michal $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
700    1_
$a Dostalova, Lenka $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Marhelava, Katsiaryna $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Fidyt, Klaudyna $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Pepek, Monika $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Baranowska, Iwona $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland $u Laboratory of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
700    1_
$a Szumera-Cieckiewicz, Anna $u Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland $u Biobank, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Inderberg, Else Marit $u Translational Research Unit, Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway $1 https://orcid.org/0000000261473536
700    1_
$a Wälchli, Sébastien $u Translational Research Unit, Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway $1 https://orcid.org/0000000158691746
700    1_
$a Granica, Monika $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland $u Doctoral School, Medical University of Warsaw, Warsaw, Poland $u Laboratory of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
700    1_
$a Graczyk-Jarzynka, Agnieszka $u Laboratory of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
700    1_
$a Majchrzak, Martyna $u Faculty of Chemistry, Wroclaw University of Science and Technology, Wroclaw, Poland
700    1_
$a Poreba, Marcin $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Faculty of Chemistry, Wroclaw University of Science and Technology, Wroclaw, Poland $u Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland
700    1_
$a Gehlert, Carina Lynn $u Division of Antibody-Based Immunotherapy, Department of Medicine II, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany
700    1_
$a Peipp, Matthias $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Division of Antibody-Based Immunotherapy, Department of Medicine II, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany
700    1_
$a Firczuk, Malgorzata $u Laboratory of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
700    1_
$a Prochorec-Sobieszek, Monika $u Division of Antibody-Based Immunotherapy, Department of Medicine II, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany
700    1_
$a Winiarska, Magdalena $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland $u Laboratory of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland $1 https://orcid.org/0000000156053329
773    0_
$w MED00190079 $t Oncoimmunology $x 2162-402X $g Roč. 13, č. 1 (2024), s. 2362454
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38846084 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134304 $b ABA008
999    __
$a ok $b bmc $g 2143399 $s 1225436
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 13 $c 1 $d 2362454 $e 20240604 $i 2162-402X $m Oncoimmunology $n Oncoimmunology $x MED00190079
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options